SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 15, 2025

Primary Completion Date

July 5, 2026

Study Completion Date

September 6, 2026

Conditions

Nephrotic Syndrome

Interventions

DRUG

Dapagliflozin

Dapagliflozin 10 mg PO once daily for 6 months

DRUG

Empagliflozin

Empagliflozin 10 mg PO once daily for 6 month

OTHER

Standard Therapy

immunosuppressive therapy and renoprotective agents for 6 months

Trial Locations (1)

Urology & Nephrology Center, Mansoura University, Al Mansurah

All Listed Sponsors

lead

Mansoura University

OTHER

NCT07214818 - SGLT2 Inhibitors in Adult Primary Nephrotic Syndrome | Biotech Hunter | Biotech Hunter